@booklet {7423,
	title = {Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens},
	journal = {Leukemia and Lymphoma},
	year = {2016},
	note = {Export Date: 21 February 2017Article in Press},
	month = {2016},
	pages = {1 - 8},
	abstract = {Monoclonal immunoglobulin deposition disease (MIDD) is characterized by non-organized immunoglobulin-fragments along renal basement membranes with subsequent organ deterioration. Treatment is directed against the immunoglobulin-producing clone. We treated 18 MIDD patients with bortezomib-based regimens (12 received bortezomib-dexamethasone, 6 bortezomib-dexamethasone with cyclophosphamide). Eleven (61\%) patients achieved a hematologic response, but only 6 (33.3\%) reached to a complete (CR) or very good partial response (VGPR). Regarding renal outcomes 77.8 and 55.6\% had >=30 and >=50\% reduction of proteinuria, respectively, but 33.3\% ended up in end-stage renal disease (ESRD). Among patients with CR or VGPR, median eGFR improvement was 7.7 ml/min/1.73~m2 and none progressed to ESRD, but no significant renal recovery was observed in patients achieving a partial response or less, with 50\% progressing to dialysis. Pretreatment eGFR seems to influence renal prognosis. Bortezomib-based treatment is considered an effective approach in MIDD and reaching to a deep hematologic response (>=VGPR) conditionally controls further renal declining. {\textcopyright} 2016 Informa UK Limited, trading as Taylor \& Francis Group},
	keywords = {bortezomib, ESRD, MIDD, proteinuria, renal response},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85006132730\&doi=10.1080\%2f10428194.2016.1267349\&partnerID=40\&md5=71d7ffe1b458a1fc513a1098e233e3b9},
	author = {Ziogas, D.C. and Kastritis, E. and Terpos, E. and Roussou, M. and Migkou, M. and Gavriatopoulou, M. and Spanomichou, D. and Eleutherakis-Papaiakovou, E. and Fotiou, D. and Panagiotidis, I. and Kafantari, E. and Psimenou, E. and Boletis, I. and Vlahakos, D.V. and Gakiopoulou, H and Matsouka, C. and Dimopoulos, M.A.}
}
